

Clinical Trial Protocol

Iranian Registry of Clinical Trials

25 Jun 2026

Memantine add on to treatment of refractory obsessive compulsive disorder

Protocol summary

Summary

Several case reports have reported efficacy of anti-glutamatergic medications for the treatment of OCD. The objective of this study was to investigate the efficacy of Memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with resistant OCD. Participants in the study will be 72 Patients referred to the Anxiety Disorders Clinic of Farshchian Hospital who have primary diagnosis of resistant Obsessive Compulsive Disorder, and are accepted for treatment at the clinic. The patients will be divided randomly in two groups to receive 10 mg per day Memantine or placebo for 12 weeks. Severity of disorder will be measured with YBOCS and CGI Scale at the beginning of the intervention and every 4 weeks.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138712141743N1**

Registration date: **2009-10-12, 1388/07/20**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2009-10-12, 1388/07/20

Registrant information

Name

Mohammad Haghighi

Name of organization / entity

Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 81 1827 4184

Email address

haghighi@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Research Center for Behavioral Disorder and Substance Abuse, Hamadan University of Medical Sciences

Expected recruitment start date

2009-09-01, 1388/06/10

Expected recruitment end date

2010-03-01, 1388/12/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Memantine add on to treatment of refractory obsessive compulsive disorder

Public title

Memantine add on to treatment of refractory obsessive compulsive disorder: A double-blind clinical trial

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Suffering from OCD, taking a therapeutic dose of a SSRI or Clomipramine, at least for 12 weeks, Y_BOSC score of 16 or greater Exclusion criteria: primary diagnosis of psychosis or bipolar mood disorder, substance abuse or dependency, uncontrolled medical condition, having had a previous trial of Memantine, pregnancy or breast feeding, rising liver enzymes to more than twice of normal range during intervention, presence of MDD

Age

No age limit

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 72

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Hamadan University of Medical sciences

Street address

Hamadan, Hamadan university of Medical science

City

Hamadan

Postal code

Approval date

2009-05-10, 1388/02/20

Ethics committee reference number

38374/9/35/16

Health conditions studied

1

Description of health condition studied

Obsessive- Compulsive Disorder

ICD-10 code

F42

ICD-10 code description

Obsessive-compulsive disorder

Primary outcomes

1

Description

Severity of symptoms of OCD

Timepoint

4 weeks

Method of measurement

Y_BOCS and CGI Scale

Secondary outcomes

empty

Intervention groups

1

Description

Memantine, 10 mg, BD, for 12 weeks

Category

Treatment - Drugs

2

Description

placebo, 10 mg, BD, for 12 weeks

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Farshchian Hospital of Hamadan.

Full name of responsible person

Dr. Mohammad Haghghi

Street address

Honaresatan street

City

Hamadan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Research Center for Behavioral Disorder and Substance Abuse, Hamadan University of Medical Sciences

Full name of responsible person

Dr Ali Ghaleiha

Street address

Honarestan street, Farshchian Hospital

City

Hamadan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Research Center for Behavioral Disorder and Substance Abuse, Hamadan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Name of organization / entity**

Hamadan University of medical Sciences

Full name of responsible person

Dr. Hassan Hafezian

Position

Resident of Psychiatry

Other areas of specialty/work**Street address**

Farshchian Hospital

City

Hamadan

Postal code**Phone**

+98 81 1827 4184

Fax**Email**

hhafezian@yhoo.com

Web page address**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Hamadan university of Medical sciences

Full name of responsible person

Mohammad Haghighi

Position

Psychiatrist, Assistant Professor

Other areas of specialty/work**Street address**

Farshchian Hospital

City

Hamadan

Postal code**Phone****Fax****Email**

dr_haghighi_ps@yahoo.com

Web page address**Person responsible for updating data****Contact****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty